Edition:
India

Aratana Therapeutics Inc (PETX.OQ)

PETX.OQ on NASDAQ Stock Exchange Global Market

5.00USD
2:29am IST
Change (% chg)

$-0.07 (-1.38%)
Prev Close
$5.07
Open
$5.14
Day's High
$5.14
Day's Low
$4.97
Volume
132,156
Avg. Vol
109,098
52-wk High
$8.25
52-wk Low
$4.81

Latest Key Developments (Source: Significant Developments)

Aratana Therapeutics Granted Conditional License For A Canine Osteosarcoma Therapeutic
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Advaxis Inc ::ARATANA THERAPEUTICS GRANTED CONDITIONAL LICENSE FOR A CANINE OSTEOSARCOMA THERAPEUTIC.ARATANA THERAPEUTICS-U.S. DEPARTMENT OF AGRICULTURE CENTER FOR VETERINARY BIOLOGICS GRANTED CONDITIONAL LICENSE​ FOR CANINE OSTEOSARCOMA VACCINE,AT-014.  Full Article

Aratana Therapeutics Says Study Did Not Achieve Protocol-Defined Efficacy Success Criteria
Saturday, 16 Dec 2017 

Dec 15 (Reuters) - Aratana Therapeutics Inc ::ARATANA THERAPEUTICS ANNOUNCES STUDY RESULTS FOR AT-016.ARATANA THERAPEUTICS INC - ARATANA'S LICENSE PARTNER RESPONSIBLE FOR DEVELOPMENT OF AT-016 SHARED RESULTS OF A PIVOTAL STUDY.ARATANA THERAPEUTICS - RECEIVED TOP-LINE PIVOTAL FIELD EFFECTIVENESS STUDY RESULTS FOR AT-016.ARATANA THERAPEUTICS - PARTNER RESPONSIBLE FOR AT-016 SHARED RESULTS OF PIVOTAL STUDY, WHICH DID NOT ACHIEVE PROTOCOL-DEFINED EFFICACY SUCCESS CRITERIA.ARATANA THERAPEUTICS INC - AS PART OF CO'S EXCLUSIVE COMMERCIAL LICENSE FOR DOGS WITH OSTEOARTHRITIS IN U.S., CO FUNDED CLINICAL STUDY & OTHER WORK.ARATANA THERAPEUTICS - CO ANTICIPATES AFTER PARTNER EVALUATED STUDY RESULTS, PARTIES TO DETERMINE IF COLLABORATION TO BRING THERAPEUTIC TO MARKET TO CONTINUE.  Full Article

Aratana Therapeutics Announces Proposed Public Offering
Tuesday, 28 Nov 2017 

Nov 27 (Reuters) - Aratana Therapeutics Inc ::ARATANA THERAPEUTICS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING.ARATANA THERAPEUTICS INC - ‍COMMENCING AN UNDERWRITTEN REGISTERED PUBLIC OFFERING OF $35 MILLION OF SHARES OF ITS COMMON STOCK​.ARATANA THERAPEUTICS INC - ‍ALL OF SHARES ARE BEING OFFERED BY ARATANA THERAPEUTICS​.  Full Article

ELANCO, ARATANA ANNOUNCE POSITIVE OPINION ON GALLIPRANT IN EUROPE
Friday, 10 Nov 2017 

Nov 10 (Reuters) - Elanco Animal Health::ELANCO, ARATANA ANNOUNCE POSITIVE OPINION ON GALLIPRANT® (GRAPIPRANT TABLETS) IN EUROPE.CO, ARATANA THERAPEUTICS ANNOUNCED EMA'S CVMP ADOPTED POSITIVE OPINION TO RECOMMEND MARKETING AUTHORIZATION OF GALLIPRANT IN EU.FOLLOWING THE POSITIVE OPINION, EC WILL COMPLETE REGULATORY PROCESS FOR FINAL DECISION ON MARKETING AUTHORISATION IN EARLY 2018.  Full Article

Aratana Therapeutics reports Q3 loss per share of $0.21
Friday, 3 Nov 2017 

Nov 2 (Reuters) - Aratana Therapeutics Inc :Aratana Therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.21.Q3 revenue $6.2 million.  Full Article

Aratana Therapeutics announces launch of Entyce
Saturday, 14 Oct 2017 

Oct 13 (Reuters) - Aratana Therapeutics Inc :Aratana Therapeutics announces launch of Entyce® (capromorelin oral solution).Aratana Therapeutics - co is making Entyce commercially available to veterinarians in United States for appetite stimulation in dogs​.  Full Article

Aratana Therapeutics granted FDA approval of Nocita
Tuesday, 16 Aug 2016 

Aratana Therapeutics Inc : Aratana Therapeutics granted FDA approval of Nocita® (bupivacaine liposome injectable suspension) .Anticipates Nocita will be commercially available to veterinarians in fall of 2016.  Full Article

Aratana posts Q2 EPS $0.61
Friday, 5 Aug 2016 

Aratana Therapeutics Inc : Q2 earnings per share $0.61 . Aratana therapeutics reports second quarter 2016 financial results .Q2 revenue $38 million versus $45 million.  Full Article

Aratana Therapeutics posts Q2 earnings per share $0.61
Friday, 5 Aug 2016 

Aratana Therapeutics Inc : Q2 revenue $38 million versus $230,000 . Aratana Therapeutics reports second quarter 2016 financial results .Q2 earnings per share $0.61.  Full Article

Aratana Therapeutics files for FDA approval of Nocita
Thursday, 30 Jun 2016 

Aratana Therapeutics Inc : Aratana Therapeutics files for FDA approval of Nocita(bupivacaine liposome injectable suspension) . Says animal drug user fee act (ADUFA) date for approval is August 28, 2016 . Aratana anticipates Nocita will be commercially available to veterinarians in fall of 2016 .Says anticipates Nocita will be commercially available to veterinarians in fall of 2016.  Full Article

BRIEF-Elanco, Aratana Announce Marketing Authorization Of Galliprant In Europe

* ELANCO, ARATANA ANNOUNCE MARKETING AUTHORIZATION OF GALLIPRANT® (GRAPIPRANT TABLETS) IN EUROPE Source text for Eikon: Further company coverage: